Table 2 |
||||
|
Serum levels of resistin, S100A12 and soluble receptor for advanced glycation end products (sRAGE) in intravenous immunoglobulin (IVIG) responding or non-responding patients with Kawasaki disease |
||||
|
Characteristic |
IVIG responders (n = 36) |
IVIG non-responders (n = 4) |
P |
|
|
|
||||
|
Boys/girls, number |
21/15 |
1/3 |
0.000 |
|
|
Age, months |
22.4 (17.2) |
30.5 (12.8) |
0.000 |
|
|
Patients with CALs, number |
7 |
2 |
0.000 |
|
|
Resistin, 102 ng/ml |
Acute stage |
0.35 (0.24) |
0.64 (0.30) |
0.032 |
|
Afebrile stage |
0.21 (0.19) ** |
0.48 (0.35) |
0.019 |
|
|
Subacute stage |
0.12 (0.05) **▲ |
0.28 (0.19) |
0.000 |
|
|
S100A12, 102 ng/ml |
Acute stage |
5.05 (3.22) |
7.92 (2.61) |
0.044 |
|
Afebrile stage |
3.99 (3.49) |
4.80 (4.26) |
0.668 |
|
|
Subacute stage |
2.35 (2.26)** ▲ |
4.98 (4.75) |
0.047 |
|
|
sRAGE, 102 pg/ml |
Acute stage |
3.07 (1.98) |
2.37 (0.96) |
0.493 |
|
Afebrile stage |
6.00 (2.78)** |
3.51 (2.64) |
0.046 |
|
|
Subacute stage |
7.19 (2.88)** |
3.65 (3.27) |
0.026 |
|
|
|
||||
|
Results are mean (SD) unless stated otherwise. CALs, coronary artery lesions; **P < 0.01 compared with acute stage; ▲P < 0.05 compared with afebrile stage. |
||||
|
Qi et al. Arthritis Research & Therapy 2012 14:R251 doi:10.1186/ar4094 |
||||
